Show simple item record

dc.contributor.advisorValenzuela Rincón, Alex 
dc.creatorLópez Salazar, Alejandro 
dc.date.accessioned2015-11-03T12:24:31Z
dc.date.available2015-11-03T12:24:31Z
dc.date.created2015-09-22
dc.date.issued2015 
dc.identifier.urihttp://repository.urosario.edu.co/handle/10336/11323
dc.descriptionImportancia: el paciente con fibrosis quística después de las complicaciones gastrointestinales y pulmonares debe enfrentar otras comorbilidades como la diabetes relacionada a su condición . Dado el aumento en la esperanza de vida y el hecho de que virtualmente todas los pacientes con esta enfermedad pueden desarrollar alteración en el metabolismo de los carbohidratos, se requiere una sensibilización frente al tema que posibilite una detección temprana de esta entidad y un tratamiento óptimo que evite las complicaciones microvasculares e impacte entre otros el crecimiento pondo-estatural en pacientes en desarrollo y la función pulmonar. Objetivo : realizar una revisión actualizada de la literatura sobre la diabetes relacionada a la fibrosis quística, destacando las indicaciones de tamización y tratamiento. Conclusión : la FQ dentro de su abordaje requiere la detección temprana de la alteración del metabolismo de los carbohidratos con una prueba de tolerancia a la glucosa , el daño del islote pancreático , la disfunción inmune, la resistencia a la insulina, el estrés oxidativo entre otros elementos fisiopatológicos conllevan a un estado de depleción de insulina que producirán un efecto negativo microvascular así como a una reducción marcada de la función pulmonar, mayores tasa de infección e incremento de la mortalidad. La piedra angular del tratamiento en pacientes con o sin hiperglicemia es la insulina que mejora tanto el estado nutricional como la función pulmonar ; nuevos antidiabéticos orales con efecto incretinas y fármacos modificadores de la enfermedad se vislumbran como alternativas al corto plazo
dc.format.mimetypeapplication/pdf
dc.language.isospa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.sourceinstname:Universidad del Rosario
dc.sourcereponame:Repositorio Institucional EdocUR
dc.subjectDiabetes relacionada con fibrosis quística, función pulmonar, insulina
dc.subject.ddcEnfermedades 
dc.subject.lembEndocrinología
dc.titleDiabetes relacionada a la fibrosis quística (DRFQ)
dc.typebachelorThesis
dc.publisherUniversidad del Rosario
dc.creator.degreeEspecialista en Endocrinología
dc.publisher.departmentFacultad de medicina
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.subject.decsFibrosis quística
dc.subject.decsEnfermedades gastrointestinales
dc.subject.decsEnfermedades pulmonares
dc.type.spaTrabajo de grado
dc.rights.accesoAbierto (Texto completo)
dc.type.hasVersioninfo:eu-repo/semantics/acceptedVersion
dc.source.bibliographicCitationAdler, Amanda I., Brian S. F. Shine, Parinya Chamnan, Charles S. Haworth, and Diana Bilton. 2008. “Genetic Determinants and Epidemiology of Cystic Fibrosis-Related Diabetes: Results from a British Cohort of Children and Adults.” Diabetes Care 31 (9): 1789–94.
dc.source.bibliographicCitationAli, Bassam R. 2009. “Is Cystic Fibrosis-Related Diabetes an Apoptotic Consequence of ER Stress in Pancreatic Cells?” Medical Hypotheses 72 (1): 55–57.
dc.source.bibliographicCitationAmerican Diabetes Association. 2010. “Diagnosis and Classification of Diabetes Mellitus.” Diabetes Care 33 (Supplement_1): S62–69.
dc.source.bibliographicCitationAschner, P., J. LaSalle, M. McGill, and Global Partnership for Effective Diabetes Management. 2007. “The Team Approach to Diabetes Management: Partnering with Patients.” International Journal of Clinical Practice. Supplement, no. 157 (December): 22–30.
dc.source.bibliographicCitationCheung, M. S., N. A. Bridges, S. A. Prasad, J. Francis, S. B. Carr, R. Suri, and I. M. Balfour-Lynn. 2009. “Growth in Children with Cystic Fibrosis-Related Diabetes.” Pediatric Pulmonology 44 (12): 1223–25.
dc.source.bibliographicCitationCouce, M., T. D. O’Brien, A. Moran, P. C. Roche, and P. C. Butler. 1996. “Diabetes Mellitus in Cystic Fibrosis Is Characterized by Islet Amyloidosis.” The Journal of Clinical Endocrinology and Metabolism 81 (3): 1267–72.
dc.source.bibliographicCitationCucinotta, D., F. De Luca, A. Gigante, T. Arrigo, A. Di Benedetto, A. Tedeschi, F. Lombardo, G. Romano, and C. Sferlazzas. 1994. “No Changes of Insulin Sensitivity in Cystic Fibrosis Patients with Different Degrees of Glucose Tolerance: An Epidemiological and Longitudinal Study.” European Journal of Endocrinology / European Federation of Endocrine Societies 130 (3): 253–58.
dc.source.bibliographicCitationDodge, J. A., P. A. Lewis, M. Stanton, and J. Wilsher. 2007. “Cystic Fibrosis Mortality and Survival in the UK: 1947–2003.” The European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology 29 (3). European Respiratory Society: 522–26.
dc.source.bibliographicCitationGodbout, A., I. Hammana, S. Potvin, D. Mainville, A. Rakel, Y. Berthiaume, J-L Chiasson, L. Coderre, and R. Rabasa-Lhoret. 2008. “No Relationship between Mean Plasma Glucose and Glycated Haemoglobin in Patients with Cystic Fibrosis-Related Diabetes.” Diabetes & Metabolism 34 (6 Pt 1): 568–73.
dc.source.bibliographicCitationHameed, Shihab, John R. Morton, Adam Jaffé, Penny I. Field, Yvonne Belessis, Terence Yoong, Tamarah Katz, and Charles F. Verge. 2010. “Early Glucose Abnormalities in Cystic Fibrosis Are Preceded by Poor Weight Gain.” Diabetes Care 33 (2): 221–26.
dc.source.bibliographicCitationHardin, Dana S., Ramalingham Arumugam, Jacek Karczewski, and Daniel K. Seilheimer. 1998. “Mechanisms of Insulin Resistance in Cystic Fibrosis † 437.” Pediatric Research 43 (April): 77–77.
dc.source.bibliographicCitationHardin, Dana S., Julie Rice, Mark Rice, and Randall Rosenblatt. 2009. “Use of the Insulin Pump in Treat Cystic Fibrosis Related Diabetes.” Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society 8 (3): 174–78.
dc.source.bibliographicCitationHardin, D. S., A. LeBlanc, S. Lukenbough, and D. K. Seilheimer. 1997. “Insulin Resistance Is Associated with Decreased Clinical Status in Cystic Fibrosis.” The Journal of Pediatrics 130 (6): 948–56.
dc.source.bibliographicCitationHoll, R. W., C. Buck, C. Babka, A. Wolf, and A. Thon. 2000. “HbA1c Is Not Recommended as a Screening Test for Diabetes in Cystic Fibrosis.” Diabetes Care 23 (1): 126.
dc.source.bibliographicCitationKoch, C., H. Cuppens, M. Rainisio, U. Madessani, H. Harms, M. Hodson, G. Mastella, et al. 2001. “European Epidemiologic Registry of Cystic Fibrosis (ERCF): Comparison of Major Disease Manifestations between Patients with Different Classes of Mutations.” Pediatric Pulmonology 31 (1): 1–12.
dc.source.bibliographicCitationKoch, C., M. Rainisio, U. Madessani, H. K. Harms, M. E. Hodson, G. Mastella, S. G. McKenzie, J. Navarro, and B. Strandvik. 2001. “Presence of Cystic Fibrosis-Related Diabetes Mellitus Is Tightly Linked to Poor Lung Function in Patients with Cystic Fibrosis: Data from the European Epidemiologic Registry of Cystic Fibrosis.” Pediatric Pulmonology 32 (5). John Wiley & Sons, Inc.: 343–50.
dc.source.bibliographicCitationLanng, S., B. Thorsteinsson, M. E. Røder, J. Nerup, and C. Koch. 1994. “Insulin Sensitivity and Insulin Clearance in Cystic Fibrosis Patients with Normal and Diabetic Glucose Tolerance.” Clinical Endocrinology 41 (2): 217–23.
dc.source.bibliographicCitationLihr, M., P. Goertchen, H. Nizze, N. S. Gould, V. E. Gould, M. Oberholzer, Ph U. Heitz, and G. Kkoppel. 1989. “Cystic Fibrosis Associated Islet Changes May Provide a Basis for Diabetes: An Immunocytochemical and Morphometrical Study.” Virchows Archiv A Pathological Anatomy and Histopathology 414 (2): 179–85.
dc.source.bibliographicCitationMarshall, B. C., S. M. Butler, M. Stoddard, A. M. Moran, T. G. Liou, and W. J. Morgan. 2005. “Epidemiology of Cystic Fibrosis-Related Diabetes.” The Journal of Pediatrics 146 (5): 681–87.
dc.source.bibliographicCitationMehta, A., G. Mehta, H. Olesen, and M. Macek. 2008. “THE EUROPEAN CYSTIC FIBROSIS REGISTRY.” Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society 7: S4–5.
dc.source.bibliographicCitationMilla, C. E., W. J. Warwick, and A. Moran. 2000. “Trends in Pulmonary Function in Patients with Cystic Fibrosis Correlate with the Degree of Glucose Intolerance at Baseline.” American Journal of Respiratory and Critical Care Medicine 162 (3 Pt 1): 891–95.
dc.source.bibliographicCitationMohan, Kamlesh, Katherine L. Israel, Helen Miller, Ruth Grainger, Martin J. Ledson, and Martin J. Walshaw. 2008. “Long-Term Effect of Insulin Treatment in Cystic Fibrosis-Related Diabetes.” Respiration; International Review of Thoracic Diseases 76 (2): 181–86.
dc.source.bibliographicCitationMoran, A., P. Diem, D. J. Klein, M. D. Levitt, and R. P. Robertson. 1991. “Pancreatic Endocrine Function in Cystic Fibrosis.” The Journal of Pediatrics 118 (5): 715–23.
dc.source.bibliographicCitationMoran, A., D. Hardin, D. Rodman, H. F. Allen, R. J. Beall, D. Borowitz, C. Brunzell, et al. 1999. “Diagnosis, Screening and Management of Cystic Fibrosis Related Diabetes Mellitus.” Diabetes Research and Clinical Practice 45 (1): 61–73.
dc.source.bibliographicCitationMoran, Antoinette, Carol Brunzell, Richard C. Cohen, Marcia Katz, Bruce C. Marshall, Gary Onady, Karen A. Robinson, et al. 2010. “Clinical Care Guidelines for Cystic Fibrosis-Related Diabetes: A Position Statement of the American Diabetes Association and a Clinical Practice Guideline of the Cystic Fibrosis Foundation, Endorsed by the Pediatric Endocrine Society.” Diabetes Care 33 (12): 2697–2708.
dc.source.bibliographicCitationMoran, Antoinette, Jordan Dunitz, Brandon Nathan, Asad Saeed, Bonnie Holme, and William Thomas. 2009. “Cystic Fibrosis-Related Diabetes: Current Trends in Prevalence, Incidence, and Mortality.” Diabetes Care 32 (9): 1626–31.
dc.source.bibliographicCitationMoran, A., K. L. Pyzdrowski, J. Weinreb, B. B. Kahn, S. A. Smith, K. S. Adams, and E. R. Seaquist. 1994. “Insulin Sensitivity in Cystic Fibrosis.” Diabetes 43 (8): 1020–26.
dc.source.bibliographicCitationMozzillo, Enza, Adriana Franzese, Giuliana Valerio, Angela Sepe, Ilaria De Simone, Gianfranco Mazzarella, Pasqualina Ferri, and Valeria Raia. 2009. “One-Year Glargine Treatment Can Improve the Course of Lung Disease in Children and Adolescents with Cystic Fibrosis and Early Glucose Derangements.” Pediatric Diabetes 10 (3): 162–67.
dc.source.bibliographicCitationNousia-Arvanitakis, S., A. Galli-Tsinopoulou, and M. Karamouzis. 2001. “Insulin Improves Clinical Status of Patients with Cystic-Fibrosis-Related Diabetes Mellitus.” Acta Paediatrica 90 (5): 515–19.
dc.source.bibliographicCitationOde, Katie Larson, Brigitte Frohnert, Theresa Laguna, James Phillips, Bonnie Holme, Warren Regelmann, William Thomas, and Antoinette Moran. 2010. “Oral Glucose Tolerance Testing in Children with Cystic Fibrosis.” Pediatric Diabetes 11 (7): 487–92.
dc.source.bibliographicCitationOnady, G. M., and A. Stolfi. 2013. “Insulin and Oral Agents for Managing Cystic Fibrosis‐related Diabetes.” The Cochrane Library. Wiley Online Library. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004730.pub3/full.
dc.source.bibliographicCitationO’Riordan, Stephen M. P., Paul D. Robinson, Kim C. Donaghue, and Antoinette Moran. 2009. “Management of Cystic Fibrosis-Related Diabetes in Children and Adolescents.” Pediatric Diabetes 10 (s12). Wiley Online Library: 43–50.
dc.source.bibliographicCitationSchwarzenberg, Sarah Jane, William Thomas, Timothy W. Olsen, Trish Grover, David Walk, Carlos Milla, and Antoinette Moran. 2007. “Microvascular Complications in Cystic Fibrosis-Related Diabetes.” Diabetes Care 30 (5): 1056–61.
dc.source.bibliographicCitationSoejima, K., and B. H. Landing. 1986. “Pancreatic Islets in Older Patients with Cystic Fibrosis with and without Diabetes Mellitus: Morphometric and Immunocytologic Studies.” Pediatric Pathology / Affiliated with the International Paediatric Pathology Association 6 (1): 25–46.
dc.source.bibliographicCitationSoleimani, M., and C. D. Ulrich 2nd. 2000. “How Cystic Fibrosis Affects Pancreatic Ductal Bicarbonate Secretion.” The Medical Clinics of North America 84 (3): 641–55, x.
dc.source.bibliographicCitationStallings, Virginia A., Lori J. Stark, Karen A. Robinson, Andrew P. Feranchak, Hebe Quinton, Clinical Practice Guidelines on Growth and Nutrition Subcommittee, and Ad Hoc Working Group. 2008. “Evidence-Based Practice Recommendations for Nutrition-Related Management of Children and Adults with Cystic Fibrosis and Pancreatic Insufficiency: Results of a Systematic Review.” Journal of the American Dietetic Association 108 (5): 832–39.
dc.source.bibliographicCitationSterescu, Anca E., Bronwen Rhodes, Reuben Jackson, Annie Dupuis, Amir Hanna, David C. Wilson, Elizabeth Tullis, and Paul B. Pencharz. 2010. “Natural History of Glucose Intolerance in Patients with Cystic Fibrosis: Ten-Year Prospective Observation Program.” The Journal of Pediatrics 156 (4): 613–17.
dc.source.bibliographicCitationTsui, L. C. 1992. “The Spectrum of Cystic Fibrosis Mutations.” Trends in Genetics: TIG 8 (11): 392–98.
dc.source.bibliographicCitationVan den Berg, J. M. W., J. M. Kouwenberg, and H. G. M. Heijerman. 2009. “Demographics of Glucose Metabolism in Cystic Fibrosis.” Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society 8 (4): 276–79.
dc.source.bibliographicCitationWaugh, N., P. Royle, I. Craigie, V. Ho, L. Pandit, P. Ewings, A. Adler, P. Helms, and C. Sheldon. 2012. “Screening for Cystic Fibrosis-Related Diabetes: A Systematic Review.” Health Technology Assessment 16 (24): iii – iv, 1–179.
dc.source.bibliographicCitationWhite, H., K. Pollard, C. Etherington, I. Clifton, A. M. Morton, D. Owen, S. P. Conway, and D. G. Peckham. 2009. “Nutritional Decline in Cystic Fibrosis Related Diabetes: The Effect of Intensive Nutritional Intervention.” Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society 8 (3): 179–85.
dc.rights.ccAtribución-NoComercial-SinDerivadas 2.5 Colombia
dc.rights.licenciaEL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos.


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by-nc-nd/2.5/co/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-nd/2.5/co/

 

Reconocimientos: